Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.42 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.42 |
| ▸ | CHEK2 | O96017 | 4/20 | 0.42 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933835 | 0.91 | PDK1 (0.40) | CHEK2PDK1JAK2 | |
| SCHEMBL24933399 | 0.87 | CHEK2 (0.52) | CHEK2LIPE | |
| SCHEMBL24933255 | 0.86 | CHEK2 (0.47) | CHEK2LIPE | |
| SCHEMBL24933245 | 0.85 | CHEK2 (0.41) | CHEK2LIPE | |
| SCHEMBL24933560 | 0.84 | P2RX3 (0.41) | P2RX3P2RX2 | |
| SCHEMBL24933748 | 0.84 | CHEK2 (0.42) | CHEK2LIPE | |
| SCHEMBL24933840 | 0.83 | PRKAB2 (0.46) | — | |
| SCHEMBL24933739 | 0.83 | IRAK4 (0.36) | P2RX3P2RX2PDK1 | |
| SCHEMBL24932993 | 0.83 | DRD4 (0.39) | — | |
| SCHEMBL24933681 | 0.83 | DRD4 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |